Terrie Curran's Insider Trades & SAST Disclosures
Terrie Curran's most recent trade in Phathom Pharmaceuticals Inc was a trade of 342,500 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 27, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Terrie Curran.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Phathom Pharmaceuticals Inc | Terrie Curran | Director, President and Chief Executive | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2025 | 342,500 | 342,500 | - | - | Stock Option (Right to Buy) | |
| Phathom Pharmaceuticals Inc | Terrie Curran | Director, President and Chief Executive | Sale of securities on an exchange or to another person at price $ 6.59 per share. | 21 Jan 2025 | 19,109 | 360,465 (1%) | 0% | 6.6 | 125,884 | Common Stock |
| Arcutis Biotherapeutics Inc | Terrie Curran | Director | Sale of securities on an exchange or to another person at price $ 10.85 per share. | 11 Nov 2024 | 8,687 | 10,139 (0%) | 0% | 10.8 | 94,238 | Common Stock |
| Phathom Pharmaceuticals Inc | Terrie Curran | Director, President and Chief Executive | Sale of securities on an exchange or to another person at price $ 11.72 per share. | 15 Jul 2024 | 33,848 | 377,734 (1%) | 0% | 11.7 | 396,699 | Common Stock |
| Arcutis Biotherapeutics Inc | Terrie Curran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 27,052 | 27,052 | - | - | Stock Option (right to buy) | |
| Arcutis Biotherapeutics Inc | Terrie Curran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 10,139 | 18,826 (0%) | 0% | 0 | Common Stock | |
| Phathom Pharmaceuticals Inc | Terrie Curran | Director, President and Chief Executive | Sale of securities on an exchange or to another person at price $ 9.11 per share. | 22 Mar 2024 | 16,851 | 410,784 (1%) | 0% | 9.1 | 153,513 | Common Stock |
| Phathom Pharmaceuticals Inc | Terrie Curran | Director, President and Chief Executive | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2024 | 475,000 | 475,000 | - | - | Stock Option (Right to Buy) | |
| Phathom Pharmaceuticals Inc | Terrie Curran | Director, President and Chief Executive | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Jul 2023 | 225,000 | 0 | - | - | Stock Option | |
| Phathom Pharmaceuticals Inc | Terrie Curran | Director, President and Chief Executive | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jul 2023 | 200,000 | 389,671 (1%) | 0% | - | Common Stock | |
| Phathom Pharmaceuticals Inc | Terrie Curran | Director, President and Chief Executive | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Jul 2023 | 175,000 | 0 | - | - | Stock Option | |
| Arcutis Biotherapeutics Inc | Terrie Curran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2023 | 12,220 | 12,220 | - | - | Stock Option (right to buy) | |
| Arcutis Biotherapeutics Inc | Terrie Curran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2023 | 4,375 | 8,687 (0%) | 0% | 0 | Common Stock | |
| Phathom Pharmaceuticals Inc | Terrie Curran | Director, President and Chief Executive | Purchase of securities on an exchange or from another person at price $ 7.82 per share. | 06 Apr 2023 | 12,919 | 188,290 (0%) | 0% | 7.8 | 101,025 | Common Stock |
| Phathom Pharmaceuticals Inc | Terrie Curran | Director, President and Chief Executive | Sale of securities on an exchange or to another person at price $ 8.54 per share. | 01 Mar 2023 | 1,436 | 175,371 (0%) | 0% | 8.5 | 12,265 | Common Stock |
| Phathom Pharmaceuticals Inc | Terrie Curran | Director, President and Chief Executive | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2023 | 162,500 | 162,500 | - | - | Stock Option (Right to Buy) | |
| Phathom Pharmaceuticals Inc | Terrie Curran | Director, President and Chief Executive | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2023 | 97,500 | 182,628 (0%) | 0% | 0 | Common Stock | |
| Phathom Pharmaceuticals Inc | Terrie Curran | Director, President and Chief Executive | Sale of securities on an exchange or to another person at price $ 8.20 per share. | 19 Jan 2023 | 5,821 | 176,807 (0%) | 0% | 8.2 | 47,729 | Common Stock |
| Phathom Pharmaceuticals Inc | Terrie Curran | Director, President and Chief Executive | Sale of securities on an exchange or to another person at price $ 9.60 per share. | 21 Nov 2022 | 1,526 | 83,720 (0%) | 0% | 9.6 | 14,650 | Common Stock |
| Phathom Pharmaceuticals Inc | Terrie Curran | Director, President and Chief Executive | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2022 | 7,500 | 85,246 (0%) | 0% | 0 | Common Stock | |
| Arcutis Biotherapeutics Inc | Terrie Curran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 11,796 | 11,796 | - | - | Stock Option (Right to Buy) | |
| Arcutis Biotherapeutics Inc | Terrie Curran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 4,312 | 4,312 (0%) | 0% | 0 | Common Stock | |
| Phathom Pharmaceuticals Inc | Terrie Curran | Director, President and Chief Executive | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2022 | 12,000 | 76,595 (0%) | 0% | 0 | Common Stock | |
| Phathom Pharmaceuticals Inc | Terrie Curran | Director, President and Chief Executive | Purchase of securities on an exchange or from another person at price $ 7.41 per share. | 13 May 2022 | 20,500 | 64,595 (0%) | 0% | 7.4 | 151,835 | Common Stock |
| Arcutis Biotherapeutics Inc | Terrie Curran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2021 | 13,391 | 13,391 | - | - | Stock Option (Right to Buy) | |
| Phathom Pharmaceuticals Inc | Terrie Curran | Director, President and Chief Executive | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.95 per share. | 22 Mar 2021 | 11,513 | 11,513 (0%) | 0% | 6.9 | 80,015 | Common Stock |
| Phathom Pharmaceuticals Inc | Terrie Curran | Director, President and Chief Executive | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Mar 2021 | 11,513 | 855,687 | - | - | Stock Option (Right to Buy) | |
| Phathom Pharmaceuticals Inc | Terrie Curran | Director, President and Chief Executive | Sale of securities on an exchange or to another person at price $ 43.24 per share. | 22 Mar 2021 | 10,373 | 1,140 (0%) | 0% | 43.2 | 448,495 | Common Stock |
| Phathom Pharmaceuticals Inc | Terrie Curran | Director, President and Chief Executive | Sale of securities on an exchange or to another person at price $ 44.08 per share. | 22 Mar 2021 | 1,140 | 0 (0%) | 0% | 44.1 | 50,256 | Common Stock |
| Phathom Pharmaceuticals Inc | Terrie Curran | Director, President and Chief Executive | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2021 | 225,000 | 225,000 | - | - | Stock Option (Right to Buy) | |
| Arcutis Biotherapeutics Inc | Terrie Curran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Nov 2020 | 37,500 | 37,500 | - | - | Stock Option (Right to Buy) | |
| Phathom Pharmaceuticals Inc | Terrie Curran | Director, President and Chief Executive | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2020 | 175,000 | 175,000 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges